5,12-dihydroquinolino[2,3-b]acridine-7,14-dione and (mono and bis)-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5,12-dihydroquinolino[2,3-b]acridine-7,14-dione

Endpoint summary

Key value for chemical safety assessment

Skin sensitisation

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed (not sensitising)

Additional information:

In order to study a possible allergenic potential of the test item, three groups each of four female mice were treated daily with the test item at concentrations of 2.5 %, 5 % and 10 % (w/v) in acetone:olive oil, 4:1 (v/v) by topical application to the dorsum of each ear lobe (left and right) for three consecutive days. A control group of four mice was treated with the vehicle (acetone:olive oil, 4:1 (v/v)) only. Five days after the first topical application the mice were injected intravenously into a tail vein with radio-labelled thymidine (3H-methyl thymidine). Approximately five hours after intravenous injection, the mice were sacrificed, the draining auricular lymph nodes excised and pooled per group. Single cell suspensions of lymph node cells were prepared from pooled lymph nodes which were subsequently washed and incubated with trichloroacetic acid overnight. The proliferative capacity of pooled lymph node cells was determined by the incorporation of 3H-methyl thymidine measured in a beta- scintillation counter. No test item-related clinical signs were observed. All treated animals survived the scheduled study period.

A test item is regarded as a sensitizer in the LLNA if the exposure to one or more test concentrations resulted in 3-fold or greater increase in incorporation of 3HTdR compared with concurrent controls, as indicated by the STIMULATION INDEX (S.I.).

	Test item concentration %	S.I.
Group 2	2.5	2.3
Group 3	5	1.1
Group 4	10	1.5

Migrated from Short description of key information:
The skin sensitization potential of the test item was determined in the course of a local lymph node assay according GLP and OECD guideline 429. All animals survived until scheduled sacrifice. Clinical signs or symptoms were not observed. The derived S.I. of the treatment groups did not exceed the S.I of the control for factor 3 or more. The substance is therefore not regarded as a skin sensitizer.

Justification for classification or non-classification

Dangerous Substance Directive (67/548/EEC)

The available studies are considered reliable and suitable for classification purposes under 67/548/EEC. As a result the substance is not considered to be classified for skin sensitization under Directive 67/548/EEC,as amended for the 30th time in Directive 2008/58/EC.

                               

Classification, Labeling, and Packaging Regulation (EC) No. 1272/2008

The available experimental test data are reliable and suitable for classification purposes under Regulation 1272/2008. As a result the substance is not considered to be classified for skin sensitization under Regulation (EC) No. 1272/2008, as amended for the second time in Directive (EC 286/2011).